Parmax Pharma sets Aug 14, 2026 board meet June qtr results

Parmax Pharma schedules board meeting for June 2026 quarter results

Parmax Pharma Limited has scheduled a meeting of its board of directors on Friday, August 14, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026. The company disclosed the meeting date in a regulatory filing with BSE Limited.

The update comes at a time when the company is also in the middle of several corporate developments, including an open offer following a significant share acquisition and a preferential issue proposal that involves a change in control. For investors tracking the counter, the next set of quarterly numbers will add another datapoint to a period marked by losses, fund-raising plans, and board-level changes.

Trading window closure after results announcement

Along with the board meeting notice, Parmax Pharma said trading in the company’s securities will be closed for forty-eight hours after the announcement of the financial results. The closure is stated to be in line with SEBI regulations.

Such trading restrictions are typically linked to unpublished price sensitive information around financial results. The company’s disclosure specifies the duration of closure following the results announcement, which can be relevant for market participants planning trades around the event.

Open offer at Rs 42.80 and change in control

Parmax Pharma’s shares are set to see an open offer priced at Rs 42.80 per share, following what the disclosure describes as a significant share acquisition. The company is subject to an open offer triggered by a substantial share acquisition through a Share Purchase Agreement and a proposed preferential issue.

The identified acquirers are Dhiren Chandulal Shah and Sunil Chinubhai Shah. The event is described as a change in control at Parmax Pharma. The open offer is positioned as an exit route for existing public shareholders at a fixed price.

As per the details provided, the open offer involves 23,46,250 shares, representing 26% of the expanded capital. The maximum consideration for the offer is Rs 10.04 crore, and the escrow amount is Rs 5.20 crore.

Preferential issue plan and July 2, 2026 EGM details

Separately, Parmax Pharma scheduled an Extraordinary General Meeting (EGM) on Thursday, July 2, 2026, to seek shareholder approval to raise Rs 19.28 crore through a preferential issue of equity shares and warrants. The issue price is stated at Rs 36.50 per share.

The board of directors, at its meeting held on June 8, 2026, sanctioned the issuance of 31,37,586 equity shares and 21,45,145 convertible warrants at an issue price of Rs 36.50 each. The issue price comprises a face value of Rs 10 and a premium of Rs 26.50.

The same board meeting approved increasing authorised share capital from Rs 6 crore to Rs 10 crore. It also approved adopting a new set of Articles of Association to align with the Companies Act, 2013.

The EGM was scheduled to be held at 11:30 am IST via video conferencing. Remote e-voting was to be open from June 29, 2026, to July 1, 2026, for shareholders holding shares as of the cut-off date of June 25, 2026.

Promoter holding and market snapshot

The shareholding pattern cited in the disclosure shows promoter holding unchanged at 30.80% in the March 2026 quarter.

On the market side, the data shared shows Parmax Pharma’s share price at Rs 75.08, up Rs 1.47 (2.00%), with the timestamp shown as BSE: 25 Jun 4:00 PM.

Financial performance: FY24 to FY26 losses and revenue swings

The company has reported consistent losses over the last three fiscal years, with revenues fluctuating, as per figures cited in the provided information.

• FY 2026: revenue of Rs 12.12 crore and a loss of Rs 4.16 crore.
• FY 2025: revenue of Rs 28.20 crore and a loss of Rs 2.09 crore.
• FY 2024: revenue of Rs 11.05 crore and a loss of Rs 5.75 crore.

Parmax Pharma also reported that the widened net loss for FY26 was driven by a decline in revenue to Rs 12.12 crore and a sharp rise in finance costs to Rs 12.40 crore.

The board approved the standalone audited financial results for the quarter and year ended March 31, 2026, during a meeting held on June 03, 2026. The statutory auditors issued an unmodified opinion, as stated.

March 2026 quarter: revenue, loss, and year-on-year comparison

For the quarter ended March 31, 2026, Parmax Pharma recorded a net loss of Rs 0.5843 crore on revenue from operations of Rs 3.31 crore. In comparison, for the same period in the previous year, the net loss was Rs 1.49 crore on revenue of Rs 4.83 crore.

The company’s standalone March 2026 net sales were reported at Rs 3.31 crore, down 31.35% year-on-year.

Quarterly numbers through March 2026

The company’s quarterly result table (figures in Rs crore) provides a view of operating trends through FY26, including sales, expenditure, operating profit, and earnings per share.

Prior disclosure: June 2025 quarter loss and auditor appointment

For the quarter ended June 30, 2025, Parmax Pharma’s board approved unaudited standalone financial results showing a net loss of Rs 0.764498 crore, compared with a profit of Rs 0.01232 crore in the same quarter last year.

Revenue from operations for the June 2025 quarter was Rs 1.942311 crore, down from Rs 7.8163 crore year-on-year. Basic earnings per share for that quarter was negative Rs 2.04.

In that update, the company also approved the appointment of Mr. Samsad Alam Khan as Secretarial Auditor for a five-year term from FY 2025-26 to FY 2029-30, subject to shareholder approval.

Board and management changes referenced in disclosures

Parmax Pharma conducted an Extra Ordinary General Meeting on May 27, 2026, approving the re-appointment of Umang Alkesh Gosalia as Managing Director and the appointments of Pradeep Ramniklal Gosalia and Salma Badrudin Thobhani as Non-Executive Directors. The resolutions to appoint Ashish Atmaram Shah and Anjana Paresh Shah as Independent Directors were not passed.

A total of 2,345,178 votes were polled, and the meeting was chaired by Managing Director Umang Alkesh Gosalia. The board also approved the re-appointment of Dr. Umang Gosalia as Managing Director for five years from June 28, 2026 to June 27, 2031, subject to shareholder approval.

As per the management list provided, Umang Alkesh Gosalia is Managing Director, with Nikhil S Uchat and Ami R Shah shown as Independent Directors.

What the company says about strategy after the transaction

With completion of the transaction, the existing promoters will cease to hold promoter status and will be declassified, according to the information provided.

The new management, led by the acquirers, plans to focus on growing the existing business of manufacturing Active Pharmaceutical Ingredients (APIs) and drug intermediates and exploring related activities.

Key facts at a glance

Conclusion

Parmax Pharma’s August 14, 2026 board meeting sets the timetable for its next quarterly financial disclosure for the quarter ended June 30, 2026, alongside a stated 48-hour trading closure after results are announced.

At the same time, investors are tracking the open offer at Rs 42.80 per share, the preferential issue proposal to raise Rs 19.28 crore, and the change-in-control process described in the company’s disclosures. The next major milestones disclosed include the financial results announcement following the board meeting and the ongoing steps linked to the open offer and preferential allotment approvals.